Trending...
- Digital Watchdog Launches New myDW Cloud Services
- Atlas Home Improvement Launches Annual Helmet for Heroes Giveaway on July 4, 2025
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
VANCOUVER, British Columbia - Michimich -- Investors are excited about biotechnology stocks in the time of the novel coronavirus. The Wall Street Journal reports that small and medium biotech stocks are near record highs, with a 60% resurgence in value since March.
Indeed, the time is ripe for biotech companies to cash in on COVID-19 via pursuit of novel drug therapies and vaccines for the condition, which currently has no cure. But risky biotech companies are taking advantage of the COVID-19 market in an effort to gain more investors for pharma products which may ultimately fail.
Sources of Risk in Biotech and Pharma
The biotech industry is notorious for its high risk, so in a COVID-19 world, more than ever, investors need to look for long-term value from prospective biotech investments. Sources of risk in the biotechnology and pharma industry – even before the current environment – include:
A key aspect of investing in biotech has always been to minimize the inherent risk as much as possible. This means looking at the company's foundation and whether they are an established leader in the field. Instead of examining how companies are faring in the COVID-19 world, consider tried-and-true leaders in pharma and biotech, which are likely to play a major effort in COVID-19 due to their leadership in the space.
Opting for low-risk stocks which performed well before the economic downturn associated with the ongoing pandemic can help improve the success of your portfolio in the long term. These companies include:
The Bottom Line
Biotech investors should focus on long-term investing strategies with proven, big pharma companies. They should avoid small, undercapitalized biotech companies that are simply chasing trends.
Indeed, the time is ripe for biotech companies to cash in on COVID-19 via pursuit of novel drug therapies and vaccines for the condition, which currently has no cure. But risky biotech companies are taking advantage of the COVID-19 market in an effort to gain more investors for pharma products which may ultimately fail.
Sources of Risk in Biotech and Pharma
The biotech industry is notorious for its high risk, so in a COVID-19 world, more than ever, investors need to look for long-term value from prospective biotech investments. Sources of risk in the biotechnology and pharma industry – even before the current environment – include:
- Companies' acquisition by other companies
Biotech is a fast-paced and dynamic world, and companies may join forces to work on a shared goal. GlaxoSmithKline has acquired 21 companies over the past decade alone, according to Crunchbase. In an alternative scenario, two companies may race towards a cure, with one company inevitably losing out. - Drugs failing in clinical trials after seeming promising in the preclinical world
While it may take ten years just for a drug to enter the clinical trials process from the laboratory, this protracted timeframe may not spell success. In 2019, Merck's cancer immunotherapy Keytruda, one of the company's strongest drugs, failed in Phase 3 clinical trials for treatment of a specific type of liver cancer. Also in 2019, Bristol Myers Squibb's Obdivo failed in a Phase 3 brain cancer trial.
More on Michimich.com- BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
- Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
- CMR Mechanical Shares 5 Signs Your AC May Be in Desperate Need for Repair
- Michigan SEO Group Shares 5 Proven Ways to Boost Social Media Engagement for Small Businesses
- Mussio Painting Shares The Benefits of Working with Professional Painters in Ann Arbor
- Adverse effects which cause drugs to promptly be pulled off the market
In 2004, Merck recalled another blockbuster drug, the painkiller Vioxx, after patients began suffering heart attacks and strokes.
A key aspect of investing in biotech has always been to minimize the inherent risk as much as possible. This means looking at the company's foundation and whether they are an established leader in the field. Instead of examining how companies are faring in the COVID-19 world, consider tried-and-true leaders in pharma and biotech, which are likely to play a major effort in COVID-19 due to their leadership in the space.
Opting for low-risk stocks which performed well before the economic downturn associated with the ongoing pandemic can help improve the success of your portfolio in the long term. These companies include:
- Johnson and Johnson (JNJ), a company with $82.8 billion in sales, which recently announced work on a COVID-19 vaccine and is listed at #34 in Forbes Global 2000 2020.
- Abbott Labs (ABT), which recently unveiled 5-minute point-of-care testing for the novel coronavirus which can be used at pharmacies and doctor's offices. Upon this news, the stock price rose nearly 50% from its low price of approximately $69 during the lowest point of the economic downturn to about $90 per share.
More on Michimich.com- Family Caregivers in Michigan Can Now Get Paid Through Medicaid with Family Aide Home Care
- Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
- Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
- Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
- Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
- Gilead Sciences (GLD), a company listed at #186 in the Forbes Global 2000 2020, which recently experienced new popularity as its antiviral treatment, Remdesivir, obtained fast-track FDA approval as a treatment for COVID-19.
- Pharma giant AstraZeneca (AZN) recently announced a landmark agreement with Oxford University towards making a COVID-19 vaccine a reality for millions around the world.
The Bottom Line
Biotech investors should focus on long-term investing strategies with proven, big pharma companies. They should avoid small, undercapitalized biotech companies that are simply chasing trends.
Source: Braeden Lichti
0 Comments
Latest on Michimich.com
- Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
- Top 5 Mistakes Entrepreneurs Make When Applying for SBA Loans
- Michigan Computer Supplies Expands Reach into Livingston County with New Brighton Service Offerings
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- Delta Industrial Provides Custom Flatwork for Factory Floors
- American Plastic Solutions Launches FAQ to Provide Tailored Plastic Fabrication Solutions
- AdviCoach of Southeast Michigan Helps Business Owners at Every Stage
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Atlas Home Improvement Launches Annual Helmet for Heroes Giveaway on July 4, 2025
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors